

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

NCT06364930

Status	RECRUITING
Phase	Phase 4
Sponsor	Chinese University of Hong Kong
Enrollment	412 participants

Key Eligibility Criteria

Inclusion (6)

- Patients with chronic hepatitis B on ETV, TDF or TAF monotherapy for at least 12 months.
- Known or newly diagnosed type 2 diabetes mellitus (T2D), defined as HbA1c $\geq 5.7\%$ or fasting blood sugar ≥ 5.6 mmol/L, or random blood sugar ≥ 11.1 mmol/L, or 2 hours sugar after oral glucose tolerance test ≥ 7.8 mmol/L.
- Stable use of anti-diabetic drugs in the last three months.
- Presence of compensated advanced chronic liver disease (cACLD) with liver stiffness measurement > 10.0 kPa, or significant portal hypertension (spleen stiffness measurement > 41.3 kPa), or presence any sign of portal hypertension (e.g. splenomegaly, ascites, varices)
- Aged 18 years old or above.

... and 1 more (see full listing online)

Exclusion (11)

- Patients with hepatitis C virus (HCV) infection as indicated by a positive antibody to HCV (anti-HCV) serology test.
- Patients with history of cirrhotic complications or hepatocellular carcinoma
- Patients with organ transplantation
- Patients receiving a SGLT2i
- Contraindications to SGLT2i due to renal insufficiency (GFR < 45 mL/min/1.73m²)

... and 6 more (see full listing online)

Locations (1 total)

Prince of Wales Hospital, Hong Kong, Hong Kong